...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Reducing the Oxidation Level of Dextran Aldehyde in a Chitosan/Dextran-Based Surgical Hydrogel Increases Biocompatibility and Decreases Antimicrobial Efficacy
【24h】

Reducing the Oxidation Level of Dextran Aldehyde in a Chitosan/Dextran-Based Surgical Hydrogel Increases Biocompatibility and Decreases Antimicrobial Efficacy

机译：降低基于壳聚糖/葡聚糖的外科手术水凝胶中葡聚糖醛的氧化水平可提高生物相容性并降低抗菌功效

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A highly oxidized form of a chitosan/dextran-based hydrogel (CD-100) containing 80% oxidized dextran aldehyde (DA-100) was developed as a post-operative aid, and found to significantly prevent adhesion formation in endoscopic sinus surgery (ESS). However, the CD-100 hydrogel showed moderate in vitro cytotoxicity to mammalian cell lines, with the DA-100 found to be the cytotoxic component. In order to extend the use of the hydrogel to abdominal surgeries, reformulation using a lower oxidized DA (DA-25) was pursued. The aim of the present study was to compare the antimicrobial efficacy, in vitro biocompatibility and wound healing capacity of the highly oxidized CD-100 hydrogel with the CD-25 hydrogel. Antimicrobial studies were performed against a range of clinically relevant abdominal microorganisms using the micro-broth dilution method. Biocompatibility testing using human dermal fibroblasts was assessed via a tetrazolium reduction assay (MTT) and a wound healing model. In contrast to the original DA-100 formulation, DA-25 was found to be non-cytotoxic, and showed no overall impairment of cell migration, with wound closure occurring at 72 h. However, the lower oxidation level negatively affected the antimicrobial efficacy of the hydrogel (CD-25). Although the CD-25 hydrogel’s antimicrobial efficacy and anti-fibroblast activity is decreased when compared to the original CD-100 hydrogel formulation, previous in vivo studies show that the CD-25 hydrogel remains an effective, biocompatible barrier agent in the prevention of postoperative adhesions.
机译：含有80％氧化葡聚糖醛（DA-100）的壳聚糖/葡聚糖基水凝胶（CD-100）的高度氧化形式被开发为术后辅助药物，并被发现可显着防止内窥镜鼻窦手术（ESS）形成粘连）。然而，CD-100水凝胶对哺乳动物细胞系显示出中等的体外细胞毒性，而DA-100被认为是细胞毒性成分。为了将水凝胶的用途扩展到腹部外科手术，一直在寻求使用低氧化DA（DA-25）的重新配方。本研究的目的是比较高氧化的CD-100水凝胶和CD-25水凝胶的抗菌功效，体外生物相容性和伤口愈合能力。使用微汤稀释法对一系列临床相关的腹部微生物进行了抗菌研究。通过四唑鎓还原试验（MTT）和伤口愈合模型评估了使用人类皮肤成纤维细胞的生物相容性测试。与原始的DA-100制剂相反，DA-25被发现是无细胞毒性的，并且没有显示出细胞迁移的总体损害，伤口闭合发生在72小时。然而，较低的氧化水平不利地影响了水凝胶（CD-25）的抗菌功效。尽管与原始CD-100水凝胶制剂相比，CD-25水凝胶的抗菌功效和抗成纤维细胞活性降低，但先前的体内研究表明，CD-25水凝胶在预防术后粘连方面仍然是一种有效的生物相容性屏障剂。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号